Definium Therapeutics, Inc. (DFTX)
Sector: Medicinal Chemicals & Botanical Products
Industry: Biotechnology
Definium Therapeutics, Inc.
NASDAQ:DFTXHealthcare · Biotechnology
PrePre-market+0.03%$33.28
Close$33.27+0.45%AH$33.42-0.42%Now$33.28
Close$33.27+9.59%AH$33.42-0.42%since
Mkt Cap$4.47B
Float132.23M
O/S134.37M
Inst Own86.3%
SI7.6%
Dilution
Historical Data
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 6, 2026 | 31.23 | 33.41 | 30.91 | 33.27 | 1,278,438 |
| Nov 5, 2026 | 32.26 | 32.33 | 30.17 | 30.36 | 1,915,662 |
| Nov 4, 2026 | 33.48 | 33.87 | 31.70 | 32.70 | 1,413,598 |
| Nov 3, 2026 | 32.99 | 34.62 | 32.73 | 33.41 | 1,724,242 |
| Nov 2, 2026 | 36.51 | 36.84 | 31.61 | 32.47 | 3,646,201 |
| Oct 30, 2026 | 37.24 | 37.95 | 35.87 | 36.33 | 1,076,583 |
| Oct 29, 2026 | 38.32 | 39.14 | 37.79 | 37.96 | 1,419,618 |
| Oct 28, 2026 | 36.87 | 38.43 | 36.76 | 38.10 | 1,678,216 |
| Oct 27, 2026 | 35.42 | 37.61 | 35.18 | 37.08 | 1,282,374 |
| Oct 26, 2026 | 35.60 | 36.35 | 34.74 | 35.68 | 1,054,043 |
| Oct 23, 2026 | 36.01 | 36.12 | 35.09 | 35.67 | 1,754,535 |
| Oct 22, 2026 | 35.29 | 36.23 | 35.09 | 36.00 | 2,092,961 |
| Oct 21, 2026 | 35.46 | 36.34 | 35.04 | 35.49 | 2,906,445 |
| Oct 20, 2026 | 32.99 | 35.58 | 32.77 | 35.09 | 1,746,265 |
| Oct 19, 2026 | 32.28 | 33.30 | 32.23 | 32.97 | 1,736,360 |
| Oct 16, 2026 | 34.07 | 34.15 | 32.02 | 32.10 | 1,935,259 |
| Oct 15, 2026 | 34.23 | 34.79 | 33.92 | 34.26 | 1,747,570 |
| Oct 14, 2026 | 34.20 | 34.91 | 33.65 | 34.24 | 1,762,182 |
| Oct 13, 2026 | 34.83 | 34.95 | 34.03 | 34.38 | 2,000,416 |
| Oct 12, 2026 | 36.27 | 36.30 | 34.95 | 35.20 | 1,909,077 |
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
Not availableRatings Distribution
BUY8
HOLD0
SELL0
TOTAL8
Insider Trades
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Wiley Matthew T. | Chief Commercial Officer | Sale | 3.1K | $113.3K | Sep 25, 2026 |
 Barrow Robert | Chief Executive Officer | Sale | 31.6K | $1.15M | Sep 25, 2026 |
 Karlin Daniel | Chief Medical Officer | Sale | 10.9K | $396.9K | Sep 25, 2026 |
 Roberts Brandi | Chief Financial Officer | Sale | 3.4K | $123.5K | Sep 25, 2026 |
 Sullivan Mark | Chief Legal Officer | Sale | 14.1K | $513.8K | Sep 25, 2026 |
 Krebs Andreas | Director | Option Exercise | 1.6K | $57.9K | Sep 18, 2026 |
Shareholders
86.3%
Institutional
(375)
3.4%
Insiderⓘ
(12)
3.0%
5%+ Owners
(1)
7.3%
Unattributed (incl. retail)ⓘ
Institutional86.3%
Insider3.4%
5%+ Beneficial3.0%
Unattributed (incl. retail)7.3%
Top Shareholders
| Name | Shares | % | Source |
|---|---|---|---|
BlackRock, Inc. | 11.2M | 8.4% | 13F |
FMR LLC · net of 13F· joint filing· may incl. warrants· filed Nov 2026 | 8.8M | 6.5% | 13G |
Avoro Capital Advisors LLC | 7.2M | 5.4% | 13F |
DRIEHAUS CAPITAL MANAGEMENT LLC | 6.8M | 5.1% | 13F |
DRIEHAUS CAPITAL MANAGEMENT LLC · also on 13F· may incl. warrants· filed Feb 2026 | 6.5M | 4.9% | 13G |
BlackRock, Inc. · also on 13F· may incl. warrants· filed Feb 2025 | 6.1M | 4.5% | 13G |
Jupiter Topco LLC | 5.6M | 4.2% | 13F |
Capital World Investors | 5.4M | 4.0% | 13F |
Avoro Capital Advisors LLC · also on 13F· may incl. warrants· filed Feb 2026 | 5.0M | 3.7% | 13G |
FMR LLC | 4.8M | 3.5% | 13F |
Sources: 13F, Form 4, 13D/13GO/S: 134.4M · as of 30 Jul 2026 · SEC cover page
Insiders & Institutional Holders
Insiders
- Wiley Matthew T.Chief Commercial Officer
- Barrow RobertChief Executive Officer
- Karlin DanielChief Medical Officer
- Roberts BrandiChief Financial Officer
- Sullivan MarkChief Legal Officer
- Krebs AndreasDirector
- Vallone Carol ADirector
- GRYSKA DAVID WDirector
- CRYSTAL ROGERDirector
- Adsett RogerDirector
About
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders.
Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder.
The company maintains its headquarters in New York, New York.
Key Metrics
Market Cap$4.47B
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership86.31%
based on 134.37M shares outstanding
SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
Country
US
USIPO DateNov 15, 2016
Shares Outstanding134.37M
Authorized Shares
Float132.23M
52-Week Range
$12.88$49.20
$33.27(56th percentile)
Volume
Average Daily Volume1.80M
1.28M today vs 1.80M avg(-29%)
30d Avg
1.80M
60d Avg
2.22M
90d Avg
2.14M
Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...